Bio-Techne Corporation

    Jurisdiction
    United States
    LEI
    54930073RLKQ51TILZ35
    ISIN
    US09073M1045 (TECH)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    53 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €38.96 32.2% overvalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Read full profile

    Fundamentals

    Net revenue
    €1.04B
    Gross margin
    64.8%
    EBIT
    €87.22M
    EBIT margin
    8.4%
    Net income
    €62.61M
    Net margin
    6.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €1.06B +2.1% €267.20M +326.8%
    €1.14B +7.1% €295.95M +10.8%
    €1.26B +10.4% €335.89M +13.5%

    Products

    Product Revenue
    Consumables €972.29M 93.5%
    Instruments €112.09M 10.8%
    Royalty €23.69M 2.3%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.08
    Ex date
    Payment date
    Dividend payout ratio
    68.7%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    BAUMGARTNER ROBERT V N/A -17K $56.21 -$957.82K
    Nusse Roeland N/A -17K $56.36 -$960.37K

    Congress transactions

    Name Transaction date Value
    Julie Johnson May 14, 2025 $1.00K–$15.00K
    Robert Bresnahan May 8, 2025 $1.00K–$15.00K
    Robert Bresnahan March 27, 2025 $1.00K–$15.00K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 144K $8.47M -114K Sell

    Earnings Calls

    Add to watchlist

    Notifications